News
SLGL
72.88
-0.16%
-0.12
Sol-Gel Technologies Sets October 14 KOL Investor Day for SGT-610
TipRanks · 2d ago
Sol-Gel Technologies to Host KOL Investor Day for SGT-610 on October 14, 2026
Barchart · 2d ago
Weekly Report: what happened at SLGL last week (0921-0925)?
Weekly Report · 4d ago
Weekly Report: what happened at SLGL last week (0914-0918)?
Weekly Report · 09/21 09:23
Sol-Gel’s Patidegib Gel Nears Key Milestone With Completed Phase 3 Gorlin Syndrome Study
TipRanks · 09/18 16:30
SolGel Technologies (SLGL) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
NASDAQ · 09/17 13:55
Sol-Gel Technologies Reaches Last-Patient Milestone in Phase 3 Gorlin Syndrome Trial
TipRanks · 09/17 13:17
Sol-Gel Technologies announces last patient visit in SGT-610 trial
TipRanks · 09/17 13:00
Major Investor Quietly Ramps Up Stake in Sol-Gel Technologies
TipRanks · 09/15 02:03
Weekly Report: what happened at SLGL last week (0907-0911)?
Weekly Report · 09/14 09:24
Major Investor Makes Bold Move on Sol-Gel Technologies Stock
TipRanks · 09/10 02:06
Weekly Report: what happened at SLGL last week (0831-0904)?
Weekly Report · 09/07 09:22
Major Investor Quietly Boosts Position in Sol-Gel Technologies
TipRanks · 09/04 02:11
Weekly Report: what happened at SLGL last week (0824-0828)?
Weekly Report · 08/31 09:24
Weekly Report: what happened at SLGL last week (0817-0821)?
Weekly Report · 08/24 09:24
Sol-Gel Posts Net Loss In Q2; Phase 3 Gorlin Results Due In November 2026
NASDAQ · 08/20 15:19
Sol-Gel Therapeutics: Steady SGT-610 Execution and Capital-Efficient Growth Strategy Drive Price Target Increase to $195 and Support Buy Rating
TipRanks · 08/20 14:55
Sol-Gel Technologies GAAP EPS of -$1.13, revenue of $0.59M
Seeking Alpha · 08/20 13:16
Sol-Gel Technologies Posts Q2 Loss as Pivotal Gorlin Syndrome Trial Advances Toward Late-2026 Readout
TipRanks · 08/20 12:57
Sol-Gel Technologies Q2 EPS $(1.13) Beats $(2.31) Estimate, Sales $591.000K Beat $75.000K Estimate
Benzinga · 08/20 12:42
More
Webull provides a variety of real-time SLGL stock news. You can receive the latest news about Sol Gel Tech through multiple platforms. This information may help you make smarter investment decisions.
About SLGL
Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.